HIF1A and chronic kidney disease: The genetic or pharmacological down‐ or upregulation of components of hypoxic response pathways, particularly those elements affecting HIF‐1 and HIF‐2‐related processes, is a rapidly expanding research field, involving prominent applications, for example, for cancer and chronic kidney disease (CKD) therapies (Semenza 2019; Stoumpos et al. 2024).